No Data
TD Cowen Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $10
State Street Corp's Strategic Acquisition of Sage Therapeutics Shares
Scotiabank Maintains Sage Therapeutics(SAGE.US) With Buy Rating, Maintains Target Price $17
Scotiabank Reaffirms Their Buy Rating on SAGE Therapeutics (SAGE)
Needham Maintains Sage Therapeutics(SAGE.US) With Hold Rating
Sage Therapeutics undergoes a global strategy restructuring and will lay off 165 people.
On October 17th, Glonhui reported that USA biopharmaceutical company sage therapeutics announced a global strategy restructuring, with the company laying off 165 people, accounting for about 33% of the total number of employees. In addition, the company will prioritize the commercialization of the depression drug Zurzuvae produced jointly with Bozhi, and focus on its development portfolio.